ReviewCurrent opinion in organ transplantation2012
Significance of T helper 17 immunity in transplantation.
Review in Current opinion in organ transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- The impact of gamma interferon on BK virus candidate microRNAs and related miRNAs in kidney transplant patients with BK infection.Scientific reports · 2025Article
- Natural microbial exposure populates the maternal fetal interface with diverse T cells.Frontiers in immunology · 2025Article
- Deciphering the Complexity of the Immune Cell Landscape in Kidney Allograft Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Depletion of donor dendritic cells ameliorates immunogenicity of both skin and hind limb transplants.Frontiers in immunology · 2024Article
- Disseminated Histoplasmosis with Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Recipient on Belatacept-based Immunosuppression.Journal of Brown hospital medicine · 2024Article
- Hashimoto's thyroiditis and renal transplant rejection.Journal of endocrinological investigation · 2023Article
- Article
- New insights into maladaptive vascular responses to donor specific HLA antibodies in organ transplantation.Frontiers in transplantation · 2023Review
- Skin and heart allograft rejection solely by long-lived alloreactive TScience advances · 2022Article
- Article
- Zinc Modulates the Priming of T Helper 1, T Helper 17, and T Regulatory Cells in Allogeneic and Autologous in vitro Models.Journal of inflammation research · 2022Article
- Immunogenicity in Stem Cell Therapy for Cardiac Regeneration.Acta Cardiologica Sinica · 2020Review
- IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8Oncoimmunology · 2020Article
- Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years.Clinical and experimental immunology · 2019Article
- Delayed allogeneic skin graft rejection in CD26-deficient mice.Cellular & molecular immunology · 2019Article
- Effects of resveratrol on Th17 cell-related immune responses under tacrolimus-based immunosuppression.BMC complementary and alternative medicine · 2019Article
- A novel model for dissecting roles of IL-17 in lung transplantation.Journal of thoracic disease · 2018Article
- Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells.Experimental and therapeutic medicine · 2018Article
- Human CD200 suppresses macrophage-mediated xenogeneic cytotoxicity and phagocytosis.Surgery today · 2018Article
- Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.Transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe aim of this review is to provide an overview of significance of T helper 17 (Th17) immunity in acute, chronic and antibody-mediated allograft rejection. The role of Th17 immunity in development of de-novo autoimmunity following transplantation is outlined. It will also consider the impact of Th17 immunity on transplantation tolerance. Potential therapies to target Th17 immunity are discussed. RECENT
findingsInterleukin17 (IL-17) is produced by a wide variety of immune and non-immune cells in response to injury. IL-17 production by tubular epithelial cells in response to complement activation in acute antibody-mediated rejection may perpetuate immune injury. Th17-dependent de-novo autoimmunity contributes to chronic allograft rejection. Targeting IL-17 not only inhibits Th17 immunity but also attenuates Th1 immunity by affecting the initial recruitment of immune cells to sites of inflammation and modulates innate and adaptive immune responses that ultimately lead to tissue destruction. SUMMARY: Th17 immunity is now beginning to be appreciated as a set of responses mediated not only by CD4 Th17 cells but a variety of immune cells and a plethora of cytokines that collaborate to mediate immune disorders, including transplant rejection. Development and contribution of de-novo autoimmunity to chronic rejection is increasingly appreciated. The developmental plasticity of Tregs and Th17 cells is a major hurdle to Treg-based cellular therapies for transplantation. Several biologics targeting Th17 immunity are under evaluation for autoimmune disease. It remains to be determined whether these can be used in transplantation to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.